EAM
PTGX icon

Eagle Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Eagle Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$13.6M Sell
294,280
-63,353
-18% -$2.56M 0.07% 238
2024
Q2 		$12.6M Buy
+357,633
New +$10.5M 0.07% 249

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Eagle Asset Management's PTGX Position: Q3 2024 in Review

Eagle Asset Management reduced its Protagonist Therapeutics (PTGX) stake by 18% in Q3 2024, selling an estimated $2.56M and leaving 294,280 shares worth $13.6M. The position accounts for 0.07% of the portfolio, ranked #238.

Eagle Asset Management first reported a position in PTGX in Q2 2024 and has held it in 2 quarters since. 240 funds tracked by Wall St. Rank hold PTGX as of Q3 2024.

  • Eagle Asset Management held 294,280 shares of Protagonist Therapeutics worth $13.6M as of Q3 2024.
  • Eagle Asset Management sold 63,353 Protagonist Therapeutics shares in Q3 2024, an estimated $2.56M.
  • Protagonist Therapeutics made up 0.07% of Eagle Asset Management's portfolio in Q3 2024, its #238 holding.
  • Eagle Asset Management first reported a position in Protagonist Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 240 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.